CN113501828B - 2,8-dioxaspiro [4.5] decane-1-ketone, and preparation method and application thereof - Google Patents
2,8-dioxaspiro [4.5] decane-1-ketone, and preparation method and application thereof Download PDFInfo
- Publication number
- CN113501828B CN113501828B CN202110769101.5A CN202110769101A CN113501828B CN 113501828 B CN113501828 B CN 113501828B CN 202110769101 A CN202110769101 A CN 202110769101A CN 113501828 B CN113501828 B CN 113501828B
- Authority
- CN
- China
- Prior art keywords
- compound
- pyran
- tetrahydro
- reaction
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 36
- APIPWCNIYUXQKS-UHFFFAOYSA-N 2,8-dioxaspiro[4.5]decan-1-one Chemical compound O=C1OCCC11CCOCC1 APIPWCNIYUXQKS-UHFFFAOYSA-N 0.000 claims abstract description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940126214 compound 3 Drugs 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 12
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003377 acid catalyst Substances 0.000 claims abstract description 11
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003513 alkali Substances 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims abstract description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940125904 compound 1 Drugs 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 229940125782 compound 2 Drugs 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 6
- 229910052786 argon Inorganic materials 0.000 claims abstract description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000011001 backwashing Methods 0.000 claims abstract description 3
- 238000001816 cooling Methods 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- -1 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylic acid methyl ester Chemical compound 0.000 claims description 13
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 8
- CNCMVGXVKBJYNU-UHFFFAOYSA-N methyl oxane-4-carboxylate Chemical compound COC(=O)C1CCOCC1 CNCMVGXVKBJYNU-UHFFFAOYSA-N 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 abstract description 4
- NNQDMQVWOWCVEM-UHFFFAOYSA-N 1-bromoprop-1-ene Chemical group CC=CBr NNQDMQVWOWCVEM-UHFFFAOYSA-N 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 abstract description 3
- 231100001261 hazardous Toxicity 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 6
- 239000004973 liquid crystal related substance Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 231100000086 high toxicity Toxicity 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- GJRMHIXYLGOZSE-JDFRZJQESA-N 1,2-Dihydrogalanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)CC2 GJRMHIXYLGOZSE-JDFRZJQESA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000002341 toxic gas Substances 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical group BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003976 antineoplastic alkaloid Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention provides 2,8-dioxaspiro [4.5] decan-1-one and a preparation method and application thereof, wherein the preparation method comprises the steps of adding a compound 1 into anhydrous tetrahydrofuran, cooling in an ice salt bath, slowly adding alkali under the protection of argon, dropwise adding a compound 2, and after dropwise adding is finished, heating for reaction; after the reaction is completed, extracting with ethyl acetate, and spin-drying to obtain a compound 3, wherein the alkali is preferably potassium tert-butoxide; adding the compound 3 and an acid catalyst into dichloromethane, stirring at room temperature, performing point-plate reaction completely, backwashing, filtering and spin-drying to obtain a compound 4, wherein the acid catalyst is preferably p-toluenesulfonic acid; the preparation method avoids using hazardous reagents such as bromopropylene, (lithium bis (trimethylsilyl) amide) and ozone, and is safer and more environment-friendly; the preparation method has mild reaction conditions, simple and convenient operation, high yield and stable process, and is more suitable for large-scale production; in addition, the method does not need low-temperature oxygen removal, and the reaction is easier to control.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to 2,8-dioxaspiro [4.5] decane-1-one, and a preparation method and application thereof.
Background
2,8-dioxaspiro [4.5] decan-1-one is an important organic synthetic raw material with bifunctional group, and is widely applied to the synthesis of medical intermediates, liquid crystal materials and pesticide intermediates.
The 2,8-dioxaspiro [4.5] decan-1-one is used as a raw material of a plurality of medical intermediates, and the intermediates can be used for synthesizing a plurality of medicaments, such as natural immunosuppressant FR901483 and antitumor alkaloid Pancratistin, and experiments prove that the intermediates have higher specific cytotoxic effect on 60 human cancer cell lines; ankeping (Vincristine) is named as aldehyde Vinblastine, and Vinblastine (Vinblastatine) is an antitumor botanical drug component; lycoramine (Lycoramine) is a drug acting on the nervous system, and antagonists of synthetic dopamine can treat schizophrenia; she Liqiu alkali has effects of exciting central nerve and increasing blood pressure, and can be used for treating facial paralysis, poliomyelitis sequelae, neurasthenia, vertigo, etc.
The alkyl cyclohexyl benzoate liquid crystal series has various excellent performances, is an important direction for the development of Twisted Nematic (TN) liquid crystal, and is also an important component for a high-grade liquid crystal mixing formula. The bifunctional group of 2,8-dioxaspiro [4.5] decan-1-one enables different groups to be conveniently extended, cyclohexyl is successfully embedded into long-chain liquid crystal molecules, is an important synthetic raw material and is used for synthesizing various high-grade liquid crystal molecules.
2,8-dioxaspiro [4.5] decan-1-one is also useful in the synthesis of synthetic insecticides. Such as total synthesis of Agarofuran sesquiterpene, which is a plant pesticide widely used for a long time and has a wide market prospect.
The patent WO2014159224 discloses a synthesis method of 2,8-dioxaspiro [4.5] decan-1-one, which adopts tetrahydropyran-4-carboxylic acid methyl ester as raw material, adopts easily spontaneous combustion LiHMDS [ (lithium bis (trimethylsilyl) amide) ] as alkali at-78 ℃, and reacts with high-toxicity reagent 3-bromopropylene, and the obtained product is subjected to ring closure at-78 ℃ in the presence of ozone and sodium borohydride to obtain the target compound.
The reaction conditions of the above route are harsh, the reaction is required to be carried out at a low temperature of-78 ℃, the whole process is difficult to control, and the method is not suitable for large-scale production; and various dangerous reagents are used in the reaction process, including high-toxicity bromopropylene, liHMDS needing strict waterproofing and toxic gas ozone.
Disclosure of Invention
Aiming at the defects in the prior art, the invention firstly aims at providing a preparation method of 2,8-dioxaspiro [4.5] decan-1-one, which is simple and convenient to operate and stable in process.
It is a second object of the present invention to provide 2,8-dioxaspiro [4.5] decan-1-one as described above.
The third object of the present invention is to provide the use of 2,8-dioxaspiro [4.5] decan-1-one as described above.
In order to achieve the above primary object, the solution of the present invention is:
in order to avoid the trial of high-toxicity reagents in the prior art, the tetrahydropyran-4-carboxylic acid methyl ester of a compound 1 is adopted as a raw material, and is dissociated in the presence of alkali to generate enol anions, so that the enol anions become nucleophilic reagents to attack 2- (2-bromoethoxy) tetrahydro-2H-pyran of a low-toxicity compound 2 and generate 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylic acid methyl ester of a compound 3; in the reaction process, the compound 2 has an electron-withdrawing group, so that the self-reactivity is improved, the use of dangerous reagents and severe low-temperature conditions in the reaction process are avoided, the reaction operation is simplified, and the reaction safety is improved. Deprotecting the compound 3 in an acid catalyst, wherein a lone pair electron exists on the obtained hydroxyl oxygen, the lone pair electron attacks electron-deficient carbonyl carbon, and nucleophilic substitution reaction is carried out to lose one molecule of methanol, so that intramolecular ester exchange ring closing is realized, and a target compound 4 is obtained; the method has high reaction activity, does not need low temperature condition in the reaction process, does not use toxic gas, can obtain the target compound under the room temperature condition, and is more suitable for expanded production.
The specific synthetic route is shown as follows:
the method comprises the following specific steps:
(1) Adding the tetrahydropyran-4-carboxylic acid methyl ester of the compound 1 into anhydrous tetrahydrofuran, cooling the mixture to below-10 ℃ in an ice salt bath, slowly adding alkali under the protection of argon, and maintaining the temperature of a reaction system to be below-10 ℃ in the adding process. After the addition, stirring for 30min, dropwise adding 2- (2-bromoethoxy) tetrahydro-2H-pyran of the compound 2, and after the dropwise addition is finished, heating to 0 ℃ for reaction. Pouring the mixture into ice water after the reaction is completed, extracting the mixture by ethyl acetate, and performing spin drying to obtain 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylic acid methyl ester of a compound 3;
(2) Adding 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylic acid methyl ester of the compound 3 and an acid catalyst into dichloromethane, stirring at room temperature, completely carrying out a spot plate reaction, backwashing, filtering and spin-drying to obtain 2,8-dioxaspiro [4.5] decan-1-one of the compound 4.
Preferably, in the step (1), the base is one or more selected from potassium carbonate, sodium methoxide, sodium ethoxide, potassium tert-butoxide, and sodium tert-butoxide.
Preferably, in step (1), the molar ratio of the tetrahydropyran-4-carboxylic acid methyl ester of the compound 1 to the base is 1 (1-2).
Preferably, in step (1), the reaction time is 2. + -. 0.1h.
Preferably, in the step (2), the acid catalyst is one or more selected from the group consisting of dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid and p-toluenesulfonic acid.
Preferably, in step (2), the molar ratio of methyl 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylate of compound 3 to acid catalyst is 1: (0.05-0.5).
Preferably, in step (2), the stirring time is 12. + -. 0.1h.
In order to achieve the second objective, the solution of the invention is:
2,8-dioxaspiro [4.5] decan-1-one obtained by the preparation method.
In order to achieve the third object, the solution of the invention is:
an application of 2,8-dioxaspiro [4.5] decane-1-ketone as an intermediate.
Due to the adoption of the scheme, the invention has the beneficial effects that:
firstly, the preparation method avoids using hazardous reagents such as bromopropylene, liHMDS, ozone and the like, and is safer and more environment-friendly.
Secondly, the preparation method is simple to operate, mild in condition, high in yield, stable in process and more suitable for large-scale production; in addition, low-temperature and oxygen-free conditions are not needed, and the reaction is easier to control.
Drawings
FIG. 1 is a nuclear magnetic hydrogen spectrum of 2,8-dioxaspiro [4.5] decan-1-one in example of the present invention.
Detailed Description
The invention provides 2,8-dioxaspiro [4.5] decane-1-one, a preparation method and application thereof.
The present invention will be further described with reference to the following examples.
Example 1:
the preparation method of 2,8-dioxaspiro [4.5] decan-1-one of this example comprises the following steps:
(1) 1000g of tetrahydropyran-4-carboxylic acid methyl ester of a compound 1 is added into 5L of anhydrous tetrahydrofuran, an ice salt bath is cooled to below-10 ℃, 856g of potassium tert-butoxide (t-BuOK) (1.1 eq) are slowly added under the protection of argon, after stirring for 30min, 1450g of 2- (2-bromoethoxy) tetrahydro-2H-pyran of a compound 2 (1 eq) is added dropwise, after the dropwise addition is finished, the temperature is raised to 0 ℃ for reaction for 2H, the TLC (thin layer chromatography) is completely reacted and poured into ice water, ethyl acetate is extracted (1L) 3, saturated saline is backwashed, anhydrous sodium sulfate is dried, and the mixture is dried in a spinning mode to obtain 1775.5g of 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylic acid methyl ester of a compound 3, wherein the yield is 92% and the purity is 98%.
(2) 1740g of methyl 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylate of Compound 3 and 110g of p-toluenesulfonic acid hydrate (0.1 eq) were added to 5L of methylene chloride, stirred at room temperature for 12H, the reaction was complete, the aqueous potassium carbonate solution was backwashed 3 times until the p-toluenesulfonic acid was removed, the organic phase was dried over anhydrous magnesium sulfate, and filtered and spin-dried to give 838g of 2,8-dioxaspiro [4.5] decan-1-one of the title compound 4 in 84% yield and 98.3% purity.
As shown in FIG. 1, nuclear magnetism of 2,8-dioxaspiro [4.5] decan-1-one of example 1:
1 H NMR(400MHz,CDCl 3 )δ4.37-4.22(m,2H),4.04-3.88(m,2H),3.60-3.46(m,2H),2.23(dd,J＝9.1,5.1Hz,2H),1.98(ddd,J＝13.7,8.6,3.7Hz,2H),1.58-1.43(m,2H)。
in order to obtain favorable conditions for synthesizing 2,8-dioxaspiro [4.5] decan-1-one, the invention further studies the influence of the change of reaction conditions in each reaction step on the yield of the reaction product in the step, and intensively discusses key influencing factors of the compounds 1 to 3 in the reaction step (1) and the compounds 3 to 4 in the reaction step (2).
In the step (1), the yield was different when the base composition and the equivalent were different, as shown in table 1.
TABLE 1
| Serial number | Alkali | Equivalent (eq) | Yield (%) |
| Example 1 | Potassium tert-butoxide | 1.1 | 92 |
| Example 2 | Sodium methoxide | 1.1 | 62 |
| Example 3 | Sodium ethoxide | 1.1 | 65 |
| Example 4 | Potassium carbonate | 1.1 | 51 |
| Example 5 | Sodium tert-butoxide | 1.1 | 75 |
| Example 6 | Potassium tert-butoxide | 1 | 87 |
| Example 7 | Potassium tert-butoxide | 1.5 | 82 |
| Example 8 | Potassium tert-butoxide | 2 | 74 |
Examples 2 to 5, compared with example 1, different alkali components were used for the reaction, and the reaction results show that potassium tert-butoxide has better reactivity than sodium methoxide, sodium ethoxide, potassium carbonate and sodium tert-butoxide, so that compound 1 is easier to form enol anions. Examples 6 to 8, compared with example 1, the amount of potassium tert-butoxide used in step 1 was changed, and the reaction results showed that increasing or decreasing the amount of potassium tert-butoxide used in example 1 resulted in a decrease in the reaction yield.
In step (2), when the components and the equivalent of the acid catalyst were different, the yield was also different as shown in table 2.
TABLE 2
Examples 9 to 11, comparative example 1, reactions with different acid catalysts were carried out; the reaction result shows that the p-toluenesulfonic acid has better catalytic activity than dilute hydrochloric acid, dilute sulfuric acid and dilute phosphoric acid. Further, comparative examples 12 to 14 further discuss the amount of p-toluenesulfonic acid used; the reaction results show that on the basis of the example 1, increasing the dosage promotes the occurrence of side reactions, so that the reaction yield is reduced; reducing the amount of the catalyst reduces the reaction rate, so that the reaction yield is reduced under the same reaction time.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. It will be readily apparent to those skilled in the art that various modifications to these embodiments and the generic principles defined herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above-described embodiments. Those skilled in the art should appreciate that many modifications and variations are possible in light of the above teaching without departing from the scope of the invention.
Claims (3)
1. A preparation method of 2,8-dioxaspiro [4.5] decan-1-one is characterized in that: the synthetic route is as follows:
the method comprises the following specific steps:
(1) Adding tetrahydropyran-4-carboxylic acid methyl ester of a compound 1 into anhydrous tetrahydrofuran, cooling an ice salt bath to below-10 ℃, adding alkali at constant temperature under the protection of argon, stirring for 30min after adding, then dropwise adding 2- (2-bromoethoxy) tetrahydro-2H-pyran of a compound 2, heating to 0 ℃ after completing dropwise adding, reacting completely, pouring into ice water, extracting with ethyl acetate, and spin-drying to obtain 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylic acid methyl ester of a compound 3;
(2) Adding 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylic acid methyl ester of compound 3 and an acid catalyst into dichloromethane, stirring at room temperature, completely carrying out a point plate reaction, carrying out backwashing, filtering and spin-drying to obtain 2,8-dioxaspiro [4.5] decan-1-one of compound 4;
in the step (1), the alkali is selected from more than one of potassium carbonate, sodium methoxide, sodium ethoxide, potassium tert-butoxide and sodium tert-butoxide;
in the step (1), the reaction time is 2 +/-0.1 h;
in the step (2), the acid catalyst is selected from more than one of dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid and p-toluenesulfonic acid;
in the step (2), the molar ratio of the methyl 4- (2- ((tetrahydro-2H-pyran-2-yl) oxy) ethyl) tetrahydro-2H-pyran-4-carboxylate of the compound 3 to the acid catalyst is 1: (0.05-0.5).
2. The process of claim 1 for the preparation of 2,8-dioxaspiro [4.5] decan-1-one, wherein: in the step (1), the mole ratio of the tetrahydropyran-4-carboxylic acid methyl ester of the compound 1 to the base is 1 (1-2).
3. The process of claim 1 for the preparation of 2,8-dioxaspiro [4.5] decan-1-one, wherein: in the step (2), the stirring time is 12 +/-0.1 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110769101.5A CN113501828B (en) | 2021-07-07 | 2021-07-07 | 2,8-dioxaspiro [4.5] decane-1-ketone, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110769101.5A CN113501828B (en) | 2021-07-07 | 2021-07-07 | 2,8-dioxaspiro [4.5] decane-1-ketone, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113501828A CN113501828A (en) | 2021-10-15 |
| CN113501828B true CN113501828B (en) | 2023-02-21 |
Family
ID=78011579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110769101.5A Active CN113501828B (en) | 2021-07-07 | 2021-07-07 | 2,8-dioxaspiro [4.5] decane-1-ketone, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113501828B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139326A1 (en) * | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| WO2014159224A1 (en) * | 2013-03-14 | 2014-10-02 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| CN107663185A (en) * | 2017-11-14 | 2018-02-06 | 安徽华胜医药科技有限公司 | Synthesis method of butyrolactone derivative |
| CN107690430A (en) * | 2015-05-29 | 2018-02-13 | 巴斯夫欧洲公司 | The method for manufacturing cyclic ester |
-
2021
- 2021-07-07 CN CN202110769101.5A patent/CN113501828B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139326A1 (en) * | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| WO2014159224A1 (en) * | 2013-03-14 | 2014-10-02 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| CN107690430A (en) * | 2015-05-29 | 2018-02-13 | 巴斯夫欧洲公司 | The method for manufacturing cyclic ester |
| CN107663185A (en) * | 2017-11-14 | 2018-02-06 | 安徽华胜医药科技有限公司 | Synthesis method of butyrolactone derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113501828A (en) | 2021-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5646706B2 (en) | Method for producing C-glycoside derivative | |
| CN113501828B (en) | 2,8-dioxaspiro [4.5] decane-1-ketone, and preparation method and application thereof | |
| CN107216335B (en) | A kind of tert-butyl 1- (methylol) -3- oxa- -9- azaspiro [5.5] hendecane -9- formic acid base ester preparation method | |
| CN118598812A (en) | Synthesis method of key intermediate of huperzine A | |
| CN115286504B (en) | Method for synthesizing (R) -2- (2- (tert-butoxy) -2-oxyethyl) pentanoic acid | |
| CN112062669A (en) | Process for preparing aromatic compounds | |
| CN115894540A (en) | Preparation method of lithium tri-sec-butyl borohydride | |
| CN116685567A (en) | Hydroxy thienoimidazole derivative, vinyl thioether derivative, n-butylidene thioether derivative, and process for producing saturated straight-chain hydrocarbon-substituted thienoimidazole derivative | |
| RU2282633C9 (en) | Method for preparing 1,11-dialkyl-3,5-dihydrofuro-[2',3':3,4]-cyclohepta[c]isochromens | |
| JP2023548914A (en) | Pyrrolinone compounds and their synthesis method | |
| CN112778189A (en) | (3R,4S) -N-substituent-3-carboxylic acid-4-ethyl pyrrolidine, intermediate and lapatinib | |
| CN115322106B (en) | Synthesis method of trans-3-azido-1-methylcyclobutanol and trans-3-amino-1-methylcyclobutanol | |
| CN112300059B (en) | Preparation method of PF-06651600 intermediate | |
| CN114736173B (en) | Preparation method of 3- (difluoromethyl) oxetane-3-amine hydrochloride | |
| CN115260103B (en) | Preparation method of 4,5-dihalogen-1- (difluoromethyl) -1H-imidazole | |
| CN116003305B (en) | A preparation method of 5-ethyl-2-pyrrolylcarboxylic acid | |
| CN115215779B (en) | Synthesis method for synthesizing different chiral spiro compounds based on spiro ketone skeleton | |
| CN111138293B (en) | Method for synthesizing ibutilide fumarate intermediate by using microchannel reactor | |
| CN110483534B (en) | Preparation method of (2,4,5, 7-tetrahydropyrano [3,4-c ] pyrazol-7-yl) methanol | |
| CN110194760B (en) | Method for preparing 3-benzylidene-2-(7'-quinoline)-2,3-dihydro-isoindol-1-one compounds | |
| CN101343213B (en) | Allyl ether series compound and preparation thereof | |
| CN119263959A (en) | A preparation method of gliclazide intermediate 1,2-cyclopentanediethanol | |
| JP2680683B2 (en) | Method for producing solanesylamine derivative | |
| CN118459383A (en) | Diselenide compound and synthesis method thereof | |
| CN115215803A (en) | Preparation method of 4-halogenated-1- (difluoromethyl) -1H-imidazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |